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A B S T R A C T
Background: Exposure to bisphenols and phthalates might influence bone health. We hypothesized that exposure
to bisphenols and phthalates during fetal life has persistent effects on bone development.
Objectives: To analyze the associations of fetal exposure to bisphenols and phthalates with bone health in school-
aged children.
Methods: Among 1,362 mother-child pairs participating in a population-based cohort study, we measured ma-
ternal urinary concentrations of bisphenols and phthalates at first, second and third trimester with high per-
formance liquid chromatography electrospray ionization-tandem mass spectrometry. Total body bone mineral
density (BMD) and bone area (BA) were measured using dual-energy X-ray absorptiometry (DXA) at 6 and 10
years, and were both used to calculate bone mineral content (BMC) and area-adjusted BMC (aBMC, a measure of
volumetric BMD).
Results: Maternal bisphenol concentrations were not associated with childhood bone measures at 6 years. After
adjustment for covariates and multiple testing correction, an interquartile range increase in maternal first tri-
mester bisphenol S (BPS) concentrations was associated with lower BMD and aBMC at 10 years (−6.08 (95%
confidence interval (CI), −9.97 to −2.19) mg/cm2 and -0.12 (95% CI, −0.20 to −0.04) g). Maternal third
trimester low molecular weight (LMW) phthalate concentrations were associated with higher aBMC at 6 years
whereas, maternal third trimester di-n-octylphthalate (DNOP) concentrations were associated with lower aBMC
at 10 years. However, these associations did not remain statistically significant after multiple testing correction.
Discussion: Maternal first trimester BPS concentrations are associated with lower BMD and aBMC in school-aged
children. These findings should be considered as hypothesis generating and need further replication and ex-
ploration of potential underlying mechanisms.
1. Introduction
Early-life exposure to environmental factors may lead to
adaptations that permanently affect skeletal development and subse-
quently predispose individuals to impaired bone health and osteo-
porosis during the life course (Cooper et al., 2006). Endocrine disruptor
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chemicals (EDCs), such as bisphenols and phthalates, are adverse en-
vironmental factors which can alter the systemic hormonal regulation
of the bone remodeling process and the skeletal formation (Agas et al.,
2013). Bisphenols and phthalates are able to cross the placenta-blood
barrier and may affect the developing fetus (Schonfelder et al., 2002;
Silva et al., 2004). They act as selected modulators of estrogen, an-
drogen, thyroid, and other receptors by activating several signaling
cascades (Schantz and Widholm, 2001). These hormones play a major
role in bone formation and remodeling, so disruption might affect bone
strength, architecture, and density parameters such as the bone mineral
density (BMD) and content (BMC), the bending force, the hardness, and
the plasticity of bones (Miettinen et al., 2005; Hermsen et al., 2008;
Lind et al., 2009; Finnila et al., 2010; Rowas et al., 2012).
Thus far, studies on the associations of bisphenol and phthalates
with skeletal health in humans are scarce. Small studies among post-
menopausal women suggested that bisphenol A (BPA) and phthalate
exposure may unfavorably affect bone homeostasis, which might lead
to osteoporosis (Vitku et al., 2018; Min and Min, 2014). Fetal life seems
to be a critical period for EDCs exposure because organs and systems
are changing more rapidly during this period (Golub et al., 2004;
Anway et al., 2005). To the best of our knowledge, no previous studies
have been performed focused on the early-life exposure to bisphenols
and phthalates in relation to bone health in humans. In addition, ex-
perimental animal studies reported sex-dependent associations. After
exposure to BPA and phthalates in early-life, an increased BMC was
observed among male rodents, whereas either a decreased BMC or an
unchanged BMC was observed among female rodents (Lejonklou et al.,
2016; Pelch et al., 2012; Chin et al., 2018). Based on these previous
studies, we hypothesized that fetal exposure to bisphenols and phtha-
lates has adverse sex-specific effects on childhood bone development.
Therefore, in a population-based cohort of 1,362 mothers and their
children, we examined the associations of fetal bisphenol and phthalate
exposure with bone health outcomes in school age children. We ex-
plored whether any association differed for boys and girls.
2. Methods
2.1. Study design
This study was embedded in the Generation R Study, a population-
based prospective cohort study among 9,778 mothers and their children
followed from early fetal life onwards in Rotterdam, the Netherlands
(Kooijman et al., 2016). Bisphenol and phthalate concentrations were
measured among a subgroup of 1,405 mothers with three urine samples
available in pregnancy and whose singleton children also participated
in postnatal studies (Philips et al., 2018). We excluded mothers without
information on bisphenol and phthalate urinary concentrations for at
least one trimester during pregnancy and whose children had no in-
formation about bone health at both 6 and 10 years. The population for
analysis comprises 1,362 mother-child pairs (1,335 at 6 years and
982 at 10 years; flow chart is given in Supplemental Fig. S1). The study
protocol underwent human subjects review at Erasmus Medical Center,
Rotterdam, The Netherlands (MEC 198.782.2001.31, MEC-2007-413).
Mothers provided written informed consent for themselves and their
children (World Medical Association, 2013).
2.2. Maternal bisphenol and phthalate concentrations
Bisphenol and phthalate concentrations were measured in a spot
urine sample obtained from each participant at early (median 12.9
weeks of gestation, 25th,75th percentiles 12.1, 14.5), mid (median 20.4
weeks of gestation, 25th,75th percentiles 20.4, 20.9) and late (median
30.21 weeks of gestation, 25th,75th percentiles 29.9, 30.8) pregnancy.
These periods were considered as first, second and third trimester. All
urine samples were collected between February 2004 and July 2005,
and stored at −20 °C in polypropylene vials. Quantitative detection of
phthalate metabolites was achieved utilizing a solid-phase extraction
method and detection of bisphenols was achieved utilizing a liquid-li-
quid extraction (HPLC-ESI-MS/MS), both performed by a high perfor-
mance liquid chromatography electrospray ionization-tandem mass
spectrometry. Further details on collection, transportation, and analysis
methodology have been described previously (Philips et al., 2018). We
grouped bisphenols together and grouped phthalate metabolites ac-
cording to their molecular weight categories and parent compounds.
Individual bisphenol and phthalate metabolites were only included in
groups and assessed individually if, less than 80% of the sample con-
centrations were below the limit of detection (LOD). We calculated the
weighted molar sums for groups representing total bisphenols, low-
molecular-weight (LMW) phthalates, high-molecular-weight (HMW)
phthalates, and for two subgroups within HMW phthalates, namely di-
2-ethylhexylphthalate (DEHP) and di-n-octylphthalate (DNOP) meta-
bolites. Phthalic acid (PA) was analyzed separately as a proxy for total
phthalate exposure. Bisphenol and phthalate concentrations below LOD
were substituted by LOD/√2 (Philips et al., 2018). To account for ur-
inary dilution, urinary concentrations of phthalates and bisphenols
were converted to μg/g creatinine (for the separate metabolites) or
μmol/g creatinine (for the metabolite groups). To reduce the potential
for exposure misclassification due to temporal variability, we calculated
the overall mean exposure during pregnancy by summing the first,
second and third trimester bisphenol and phthalate concentrations and
dividing by three.
2.3. Bone mineral density measurements
At both 6 and 10 years, total body bone mineral density was mea-
sured using a dual-energy X-ray absorptiometry (DXA) scan (iDXA,
General Electrics— Lunar, 2008, Madison, WI, USA), as previously
described (Heppe et al., 2013). Scans were analyzed using enCORE
version 13.6. In a sample of non-obese adults, the coefficient of varia-
tion of total body BMC using the GE Lunar iDXA system was 0.5%,
showing high precision for assessing bone composition (Rothney et al.,
2012). The official positions of the International Society for Clinical
Densitometry (ISCD) on DXA evaluation in children and adolescents
(males and females 5–19 years) indicates that when technically fea-
sible, the lumbar spine and whole body BMD and BMC are the most
accurate and reproducible skeletal sites for performing BMD and BMC
(Bianchi et al., 2010). In our analyses, we used areal total body less
head BMC, bone area (BA) and BMD as recommended by the ISCD
(Lewiecki et al., 2008). BMD measured by DXA was expressed as BMC
(in g) per projected BA (in cm2). BMC was calculated from BMD using
the projected bone area. Area-adjusted BMC (aBMC) was derived as a
measure of volumetric BMD by using linear regression to adjust BMC
for bone area and adding the residuals to the mean BMC (Macdonald-
Wallis et al., 2010).
2.4. Covariates
Information on maternal age at enrolment, parity, educational level,
ethnicity, pre-pregnancy weight, folic acid supplementation, smoking
habits and alcohol consumption was obtained from questionnaires
during pregnancy. Maternal height was measured at enrolment and pre-
pregnancy body mass index (BMI, kg/m2) was calculated. Maternal
25(OH)D concentrations in second trimester were measured in plasma
using isotope dilution liquid chromatography-tandem mass spectro-
metry. Vitamin D status was categorized, according to previously used
cut-offs and recommendations, into severely deficient (< 25.0 nmol/L),
deficient (25.0 to 49.9 nmol/L), sufficient ( 50.0 to 74.9 nmol/L) and
optimal (≥75.0 nmol/L) (Miliku et al., 2016). We obtained information
about child's sex from midwife and hospital registries. At both 6- and
10-year visits, child height was measured without shoes. Measures of
total body fat and lean mass were derived from the DXA scan.
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2.5. Statistical analysis
For all analyses, we natural log-transformed phthalate and bi-
sphenol concentrations to reduce variability and account for right
skewedness of the distribution and standardized by the interquartile
range to ease the interpretation of effect sizes. We performed linear
regression models to assess the associations of exposure to bisphenol
and phthalate (at first, second and third trimester and overall mean
during pregnancy) with childhood bone measures. Non-linearity of the
relationship was visually assessed and ruled out. Basic models include
child's sex, age and height at visit. Potential confounders were identi-
fied based on the graphical criteria for confounding by visualizing a
directed acyclic graph (DAG) presented in Supplemental Fig. S2) and
were included in the models those that changed the effect esti-
mates> 10% for at least one of the outcomes (Santos et al., 2019). To
account for the influence of body composition on bone measures, we
also adjusted for the sum of child's lean and fat mass. Analyses were
performed for the total group and by sex. Since folic acid is known to
influence the metabolism of bisphenols and phthalates (Crider et al.,
2012), we tested for statistical interaction between bisphenols and
phthalates with folic acid supplementation in these associations. We
found statistically significant interactions and thus stratified analyses
by folic acid supplementation were performed. To correct for multiple
hypothesis testing, each p-value was compared with a threshold defined
as 0.05 divided by the effective number of independent tests estimated
based on the correlation between the exposures (p-value threshold of
0.0098) (Li et al., 2012).
To examine the independent associations of maternal first, second
and third trimester phthalate and bisphenol concentrations, we per-
formed a sensitivity analysis in which the exposures at all three tri-
mesters were simultaneously included in one model, creating a mu-
tually adjusted model. Also, as sensitivity analyses, instead of using
creatinine-adjusted first, second and third trimester phthalate and bi-
sphenol concentrations, we refitted the models by adding creatinine
concentration as a separate covariate. Due to the large proportion of
concentrations below LOD for some bisphenols, we additionally per-
formed the models by categorizing the bisphenols as detected (above
LOD) and undetected (below LOD). To maintain statistical power and
reduce bias related to missing data on covariates, we performed mul-
tiple imputation according to the Markov Chain Monte Carlo method.
The percentage of missing values for covariates ranged from 0.6 to
20.2%. Ten imputed datasets were created and no substantial differ-
ences were found between the original and imputed datasets. We pre-
sent results based on pooled imputed datasets. All statistical analyses
were performed using the Statistical Package of Social Sciences version
25.0 for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Participant characteristics
Table 1 shows the characteristics of the included mothers and their
children. Non-response analyses at age 10 showed that mothers of
children without follow-up data available were more likely to have
higher urinary phthalate concentrations, be younger, of non-European
ethnicity, less educated, not take folic acid supplementation, more se-
verely vitamin D deficient and not have consumed alcohol during
pregnancy (Supplemental Tables S1 and S2). Table 2 and Supplemental
Table S3 show the concentrations and detection rates of all bisphenols
and phthalate metabolites for the total group and by sex, respectively.
The intraclass correlation coefficient for phthalates and bisphenols
across pregnancy varied between 0.01 and 0.40.
3.2. Maternal bisphenol urinary concentrations and childhood bone health
We did not observe associations of maternal total and specific
bisphenol concentrations with childhood bone measures at age 6
(Table 3 and Supplemental Tables S4 and S5). Also, no associations
were observed for maternal BPA concentrations with childhood bone
measures at both ages. In the fully adjusted model, an interquartile
range increase in maternal first trimester BPS concentration was asso-
ciated with lower childhood BMD and aBMC at 10 years (−6.08 (95%
confidence interval (CI), −9.97 to −2.19) mg/cm2 and -0.12 (95% CI,
−0.20 to −0.04) g, respectively). These associations remained sig-
nificant after adjustment for multiple testing correction (Table 3). Re-
sults of the basic models are given in Supplemental Tables S6 and S7.
We did not observe different associations between child's sex or ma-
ternal folic acid supplement use groups (Supplemental Tables S8 and
S9).
3.3. Maternal phthalate urinary concentrations and childhood bone health
In the fully adjusted model, an interquartile range increase in ma-
ternal third trimester LMW phthalate concentrations was associated
with higher childhood aBMC at 6 years (0.08 (95% CI 0.004 to 0.15) g).
Also, an interquartile range increase in maternal third trimester DNOP
concentration was associated with lower aBMC at 10 years (−0.07
(95% CI -0.14 to −0.003) g). However, none of these associations re-
mained statistically significant after multiple testing correction (Table 4
and Supplemental Tables S10 and S11). No associations were observed
for the other maternal phthalate metabolite concentrations with bone
measures at both ages. Results from the basic models are given in
Supplemental Tables S12 and S13. We observed no consistent sex-
specific differences for the associations of maternal phthalate metabo-
lite concentrations with bone health outcomes (Supplemental Table
S14). When we stratified for folic acid use, we observed that maternal
phthalate metabolite concentrations tended to be inversely associated
with bone measures in women who took folic acid supplementation but
positively associated in those that did not take folic acid supple-
mentation (Supplemental Table S15).
3.4. Sensitivity analysis
As compared to the trimester specific results as described above,
similar results for the associations of maternal bisphenol and phthalate
concentrations with childhood bone health at both ages were observed
in the mutually adjusted models (Supplemental Tables S16, S17, S18
and S19). Results of the models using the uncorrected maternal urinary
concentrations of phthalates and bisphenols (in nmol/L) and adding
creatinine as a separate covariate in the model were similar to the main
analyses with creatinine-adjusted bisphenol and phthalates concentra-
tions (Supplemental Tables S20 and S21). Similar results were also
observed when we categorized the bisphenols as detected (above LOD)
and undetected (below LOD) (Supplemental Table S22).
4. Discussion
We observed, in a population-based prospective cohort study, that
higher maternal first trimester BPS concentrations were associated with
lower childhood BMD and aBMC at 10 years, but not at 6 years.
Furthermore, maternal LMW phthalate and DNOP concentrations may
affect childhood bone health outcomes. We did not find any consistent
sex-specific associations.
4.1. Interpretation of main findings
Results from previous studies suggest that fetal life is a critical
period for EDCs exposure because organs and systems are changing
more rapidly during this period (Golub et al., 2004; Anway et al.,
2005). We examined whether fetal exposure to bisphenols and phtha-
lates has adverse, and sex-specific effects, on childhood bone develop-
ment. Urinary concentrations and detection rates of bisphenols and
C. van Zwol - Janssens, et al. Environmental Research 186 (2020) 109602
3
phthalate metabolites found in our study population were generally
lower compared to other Western studies performed in the same time
period (Casas et al., 2013; Harley et al., 2017; Philippat et al., 2014;
Valvi et al., 2013; Woodruff et al., 2011). Three cross-sectional studies
have been performed to examine the relationship between BPA level
and bone mineral density in humans but they yielded no associations
(Kim et al., 2012; DeFlorio-Barker and Turyk, 2016; Zhao et al., 2012).
To the best of our knowledge, no previous study has examined re-
lationships between other BPA analogues and bone mineral density in
humans. We observed that higher maternal first trimester BPS con-
centrations were associated with lower childhood BMD and aBMC at 10
years. These results are in line with previous in vitro studies, which
found that long-term exposure to BPS and bisphenol AF, but not BPA,
induces changes in the genome-wide gene expression assay, resulting in
developmental changes of embryonic skeletal system, enhanced osteo-
clast differentiation and hedgehog signaling pathway (Fic et al., 2015).
The differential effects of BPA analogues on skeletal process might be
related to their affinity towards cell receptors. However, no associations
were observed with bone health in children at age 6. This age depen-
dent associations may be due to a lower variability of the bone mass
outcomes at age 6 compared to age 10, precluding the detection of
associations. The effect of bisphenols and phthalates on bone devel-
opment might also only become more apparent at later ages.
In animal studies, phthalate metabolites may cause dose-dependent
fetal toxicity reflected in severe skeletal malformations and imbalance
of bone homeostasis (Agas et al., 2013). In line with these studies, in
postmenopausal women phthalate exposure was associated with lower
BMD and higher osteoporosis risk (Min and Min, 2014). In the present
study, maternal LMW phthalate concentrations were associated with
higher aBMC at 6 years and maternal DNOP concentrations were as-
sociated with lower aBMC at 10 years. However, these results should be
carefully interpreted since they did not survive multiple testing cor-
rection.
Animal studies suggest that timing of EDC exposure could be an
explanation for different findings in similar studies (Lejonklou et al.,
2016; Lind et al., 2017). We explored if there is a critical exposure
period during fetal development. We identified the first trimester to be
the critical period for the association of BPS with BMD, BMC and aBMC.
The fetal skeleton is being developed from first trimester onwards
(Timor-Tritsch et al., 1992; van Zalen-Sprock et al., 1997). These
findings suggest that exposure to BPS in the beginning of skeletal de-
velopment may have persistent effects on bone development.
Table 1
Characteristics of mothers and their children (n = 1,362).
Characteristics Total group (n = 1,362) Boys (n = 688) Girls (n = 674) p- value
Maternal characteristics
Age, mean (SD) (years) 30.6 (4.8) 30.6 (4.8) 30.5 (4.8) 0.61
Pre-pregnancy BMI, median (95% range) (kg/m2) 22.7 (18.5, 34.9) 22.7 (18.4, 35.2) 22.6 (18.5, 34.9) 0.49
Parity, n (%) 0.42
Nulliparous 829 (61.2) 426 (62.2) 403 (60.1)
Multiparous 525 (38.8) 258 (37.8) 267 (39.9)
Ethnicity, n (%) 0.64
European 839 (62.2) 429 (62.8) 410 (61.6)
Non-European 510 (37.8) 254 (37.2) 256 (38.4)
Education, n (%) 0.35
Lower 99 (7.6) 44 (6.7) 55 (8.5)
Middle 549 (42.1) 273 (41.6) 276 (42.7)
Higher 655 (50.3) 340 (51.8) 315 (48.8)
Smoking during pregnancy, n (%) 0.92
Yes 300 (24.4) 150 (24.5) 150 (24.3)
No 930 (75.6) 462 (75.5) 468 (75.7)
Alcohol consumption during pregnancy, n (%) 0.06
Yes 706 (57.7) 368 (60.3) 338 (55.0)
No 518 (42.3) 242 (39.7) 276 (45.0)
Folic acid supplementation, n (%) 0.52
Yes 879 (80.9) 453 (81.6) 426 (80.1)
No 208 (19.1) 102 (18.4) 106 (19.9)
Vitamin D, n (%) 0.58
Severely deficient 267 (20.6) 126 (19.2) 141 (22.0)
Deficient 327 (25.2) 163 (24.8) 164 (25.5)
Sufficient 318 (24.5) 165 (25.2) 153 (23.8)
Optimal 386 (29.7) 202 (30.8) 184 (28.7)
Child characteristics at age 6
Age, mean (SD) (years) 5.9 (0.2) 5.9 (0.2) 5.9 (0.2) 0.75
Height, mean (SD) (cm) 117.8 (4.9) 118.1 (5.0) 117.4 (4.8) 0.02
Bone-free mass, mean (SD) (kg) 18.3 (3.2) 18.3 (3.2) 18.3 (3.2) 0.97
Bone mineral density, mean (SD) (mg/cm2) 536.4 (43.5) 537.4 (42.5) 535.5 (44.5) 0.49
Bone mineral content, mean (SD) (g) 506.4 (82.3) 508.0 (82.3) 504.7 (82.4) 0.53
Area-adjusted bone mineral content, mean (SD) (g) 506.6 (1.0) 506.6 (1.0) 506.6 (1.0) 0.73
Bone area, mean (SD) (cm2) 939.7 (95.9) 941.3 (98.5) 938.1 (93.3) 0.60
Child characteristics at age 10
Age, mean (SD) (years) 9.7 (0.2) 9.7 (0.3) 9.7 (0.2) 0.63
Height, mean (SD) (cm) 141.0 (6.3) 141.0 (6.3) 141.0 (6.4) 0.98
Bone-free mass, mean (SD) (kg) 29.9 (6.7) 29.5 (6.4) 30.3 (7.0) 0.04
Bone mineral density, mean (SD) (mg/cm2) 677.9 (64.0) 679.2 (62.6) 676.7 (65.3) 0.53
Bone mineral content, mean (SD) (g) 921.7 (160.7) 925.1 (155.9) 918.3 (165.4) 0.51
Area-adjusted bone mineral content, mean (SD) (g) 921.7 (1.0) 921.7 (1.0) 921.7 (1.0) 0.89
Bone area, mean (SD) (cm2) 1351.7 (128.8) 1355.0 (126.9) 1348.5 (130.8) 0.43
Values are observed data and represent means (SD), medians (95% range), or number of subjects (valid %).
Differences in participant characteristics between boys and girls were evaluated using t tests for normally distributed variables, Mann-Whitney U tests for non-
normally distributed variables, and χ2 tests for categorical variables.
SD standard deviation; BMI, body mass index.
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Nevertheless, these results should be carefully interpreted since lower
detection rates for BPS in second and third trimester might have pre-
cluded the detection of associations.
Results from previous studies on sex-specific associations of EDCs
with bone health were not consistent. Fetal and neonatal exposure to
BPA increased femoral BMC among male mice but decreased femoral
mechanical strength among female mice (Pelch et al., 2012). Another
study observed that in utero and lactational exposure to low-dose BPA
elongated the femur among female rat offspring and increased cortical
thickness among male rat offspring (Lejonklou et al., 2016). In the
Table 3
Covariate-adjusted associations of maternal bisphenol concentrations with childhood bone mass.
Bisphenols Age 6 Age 10
BMD (mg/cm2) aBMC (g) BMD (mg/cm2) aBMC (g)
β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value
Total bisphenol
First trimester -1.12 (−3.38, 1.15) 0.33 -0.02 (−0.09, 0.04) 0.47 -2.90 (−6.41, 0.61) 0.11 -0.07 (−0.14, 0.01) 0.07
Second trimester 0.26 (−1.87, 2.38) 0.81 0.01 (−0.05, 0.07) 0.78 0.87 (−2.50, 4.24) 0.61 0.02 (−0.05, 0.09) 0.50
Third trimester 0.72 (−1.43, 2.87) 0.51 0.03 (−0.04, 0.09) 0.42 -0.86 (−4.21, 2.50) 0.62 -0.02 (−0.09, 0.05) 0.54
BPA
First trimester -0.54 (−2.83, 1.76) 0.65 -0.01 (−0.07, 0.06) 0.84 -1.31 (−4.86, 2.25) 0.47 -0.03 (−0.10, 0.05) 0.45
Second trimester 0.32 (−1.78, 2.41) 0.77 0.01 (−0.05, 0.07) 0.74 0.83 (−2.52, 4.17) 0.63 0.02 (−0.05, 0.09) 0.54
Third trimester 1.14 (−0.95, 3.23) 0.29 0.05 (−0.01, 0.11) 0.11 -1.20 (−4.46, 2.07) 0.47 -0.03 (−0.10, 0.04) 0.41
BPS
First trimester -2.04 (−4.55, 0.46) 0.11 -0.07 (−0.14, 0.00) 0.06 -6.08 (−9.97 - -2.19)† < 0.01 -0.12 (−0.20 - -0.04)† < 0.01
Second trimester -1.04 (−3.15, 1.07) 0.33 -0.01 (−0.07, 0.05) 0.81 -0.27 (−3.54, 3.00) 0.87 0.02 (−0.05, 0.08) 0.63
Third trimester 1.19 (−0.74, 3.11) 0.23 0.03 (−0.02, 0.09) 0.25 1.19 (−1.93, 4.32) 0.45 0.04 (−0.03, 0.10) 0.28
BPF
First trimester -0.55 (−2.95, 1.84) 0.65 -0.02 (−0.09, 0.05) 0.67 -1.56 (−5.37, 2.26) 0.42 -0.06 (−0.14, 0.02) 0.13
Second trimester NA NA NA NA
Third trimester -0.01 (−2.39, 2.37) 0.99 -0.01 (−0.08, 0.06) 0.81 1.23 (−2.54, 5.00) 0.52 0.05 (−0.03, 0.13) 0.23
Values are linear regression coefficients (β, 95% Confidence Interval) that reflect the differences in bone health for an interquartile range increase in each natural log-
transformed bisphenol urinary concentrations in μmol/g. Confounder models include child’s age, sex, height and bonefree mass, maternal age, pre-pregnancy BMI,
ethnicity and education level, parity, folic acid supplement use during pregnancy, alcohol and smoking habits (specifically during each trimester or during preg-
nancy) and vitamin D blood concentrations.
*p-value<0.05 †significant after correction for multiple testing (p- value threshold of 0.0098).
BMD (mg/cm2), bone mineral density (milligram per square centimeter); aBMC (g), area adjusted bone mineral content (grams); CI, confidence interval; BPA,
bisphenol A; BPS, bisphenol S, BPF, bisphenol F; NA, not applicable due to low detection rates.
Table 4
Covariate-adjusted associations of maternal phthalate concentrations with childhood bone mass.
Phthalates BMD (mg/cm2) Age 6 p-value BMD (mg/cm2) Age 10 p-value
p-value aBMC (g) p-value aBMC (g)
β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Phthalic acid
First trimester -0.23 (−2.25, 1.80) 0.83 -0.01 (−0.07, 0.05) 0.70 -0.25 (−3.43, 2.93) 0.88 0.01 (−0.06, 0.07) 0.83
Second trimester 0.77 (−1.71, 3.24) 0.55 0.02 (−0.05, 0.09) 0.56 -0.62 (−4.48, 3.24) 0.75 -0.02 (−0.10, 0.07) 0.71
Third trimester -0.95 (−3.19, 1.28) 0.40 -0.01 (−0.07, 0.06) 0.84 -2.76 (−6.23, 0.70) 0.12 -0.03 (−0.10, 0.04) 0.38
LMW phthalate metabolites
First trimester -0.61 (−2.89, 1.67) 0.60 -0.01 (−0.08, 0.06) 0.79 -0.92 (−4.55, 2.72) 0.62 0.01 (−0.07, 0.09) 0.81
Second trimester 0.92 (−1.44, 3.29) 0.44 0.04 (−0.03, 0.11) 0.28 -0.71 (−4.37, 2.95) 0.71 0.00 (−0.08, 0.08) 0.98
Third trimester 1.81 (−0.69, 4.30) 0.16 0.08 (0.00, 0.15)* 0.04 -0.50 (−4.36, 3.37) 0.80 0.02 (−0.06, 0.10) 0.69
HMW phthalate metabolites
First trimester -0.67 (−2.74, 1.41) 0.53 -0.03 (−0.09, 0.03) 0.27 -0.63 (−4.00, 2.75) 0.72 0.00 (−0.07, 0.07) 0.94
Second trimester 0.56 (−1.46, 2.58) 0.59 0.02 (−0.04, 0.08) 0.48 -0.02 (−3.23, 3.20) 0.99 -0.01 (−0.08, 0.05) 0.69
Third trimester 0.15 (−1.98, 2.28) 0.89 0.01 (−0.05, 0.07) 0.75 -0.04 (−3.37, 3.29) 0.98 -0.01 (−0.08, 0.06) 0.82
DEHP metabolites
First trimester -0.41 (−2.45, 1.63) 0.69 -0.03 (−0.09, 0.03) 0.33 -0.22 (−3.53, 3.09) 0.90 0.01 (−0.06, 0.08) 0.83
Second trimester 0.13 (−1.90, 2.17) 0.90 0.01 (−0.05, 0.07) 0.71 -0.52 (−3.75, 2.70) 0.75 -0.02 (−0.09, 0.05) 0.55
Third trimester 0.30 (−1.82, 2.41) 0.78 0.01 (−0.05, 0.07) 0.74 0.61 (−2.70, 3.91) 0.72 0.00 (−0.07, 0.07) 0.94
DNOP metabolites
First trimester -1.48 (−3.43, 0.47) 0.14 -0.06 (−0.11, 0.00) 0.05 -0.97 (−4.07, 2.14) 0.54 0.00 (−0.07, 0.06) 0.96
Second trimester 1.19 (−0.95, 3.34) 0.28 0.04 (−0.03, 0.10) 0.25 0.26 (−3.09, 3.61) 0.88 0.00 (−0.07, 0.07) 0.99
Third trimester -1.39 (−3.45, 0.68) 0.19 -0.04 (−0.10, 0.03) 0.25 -3.02 (−6.24, 0.20) 0.07 -0.07 (−0.14, 0.00)* 0.04
Values are linear regression coefficients (β, 95% Confidence Interval) that reflect the differences in bone health for an interquartile range increase in each natural log-
transformed phthalate urinary concentrations in μmol/g. Confounder models include child’s age, sex, height and bonefree mass, maternal age, pre-pregnancy BMI,
ethnicity and education level, parity, folic acid supplement use during pregnancy, alcohol and smoking habits (specifically during each trimester or during preg-
nancy) and vitamin D blood concentrations.
*p-value<0.05.
BMD (mg/cm2), bone mineral density (milligram per square centimeter); aBMC (g), area adjusted bone mineral content (grams); CI, confidence interval; LMW
phthalate, low molecular weight phthalate; HMW phthalate, high molecular weight phthalate; DEHP, di-2-ethylhexylphthalate; DNOP, di-n-octylphthalate.
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present study, we did not observe consistent differences in the asso-
ciations of maternal bisphenol and phthalate metabolite concentrations
with childhood bone health outcomes between boys and girls. This
might be explained by the hypothesis that differences between boys and
girls depend on the timing and nature of the EDC exposure.
Maternal dietary supplementation with methyl donors, such as folic
acid, has been shown to limit the DNA hypomethylating effect of EDCs
in early stem cell development (Dolinoy et al., 2007). Also, a higher
folate intake is associated with better bone health (Tobias et al., 2005).
Therefore, we hypothesized that folic acid supplementation may limit
the adverse effects of fetal bisphenol and phthalate exposure on bone
development. We observed that maternal phthalate metabolite con-
centrations tended to be inversely associated with bone measures in
mothers who took folic acid supplementation and positively associated
in those who did not take folic acid supplementation. These results do
not suggest a protective effect of folic acid supplement use to prevent
the adverse effects of bisphenols and phthalates. This might suggest that
DNA hypomethylation is not among the main underlying mechanisms
for the adverse effects of bisphenols and phthalates in bone develop-
ment and thus no protective effect was observed when taking folic acid
supplementation. The results observed for mothers who did not take
folic acid supplementation should be carefully interpreted taking into
account the small sample size and lack of statistical power.
The mechanisms by which EDC exposure affect bone health are not
known yet. There is some evidence regarding the capacity of EDCs to
interfere with the bone remodeling and homeostasis through the
modulation of the signaling pathways involved (Agas et al., 2013). The
EDCs activating or antagonizing these receptors can lead to an im-
balance in hormonal production, which could affect bone formation
(Agas et al., 2013). It is well established that young children and ado-
lescents show a greater susceptibility to chemical toxicants than adults
(Goldman, 1998). Further research addressing hormonal changes in
response to specific EDCs in critical periods of life may help to disen-
tangle underlying pathways.
Altogether, our results suggest that BPS, DNOP and LMW phthalate
exposure during pregnancy may have persistent effects on bone health
in childhood. Also, the first trimester of pregnancy might be a critical
period. The observed effect estimates might be small on an individual
level, but can be important on a population-based level. Small changes
in bone quality during childhood may be related to bone related dis-
eases such as osteoporosis in later life. Due to the observational design
of this study, we cannot draw conclusions about causality. Further
studies are needed to replicate these findings and investigate potential
mechanisms.
4.2. Methodological considerations
An important strength of this study is the population-based cohort
design from early life onwards, with measurements of maternal bi-
sphenol and phthalate concentrations and bone mass in a large number
of children. Of mothers with information on maternal bisphenol and
phthalate concentrations during pregnancy, information on bone health
was available for 97% of children at age 6 and 71% of children at age
10. Selection bias due to selective loss to follow-up is of concern if the
associations between maternal bisphenol and phthalate concentrations
and bone health differ between those included and not included in the
study. As shown in the non-response analyses, mothers of children with
and without follow-up data were different regarding the socio-
demographic background, lifestyle characteristics and phthalate ur-
inary concentrations. We cannot exclude the possibility of selection bias
but we believe selection bias has little influence on our findings since
we adjusted for most of these factors (Nohr and Liew, 2018). The lower
urinary concentrations of phthalate metabolites observed in included
mothers might have complicated the detection of associations due to
low variability. We assessed associations of BPA analogues such as BPS,
and of PA, a proxy for total phthalate exposure, with childhood bone
health. Since our exposure measures were based on single spot urine
sample in all three trimesters of pregnancy it may not accurately reflect
preconceptional levels. Additionally, we had no information about
neonatal exposure to bisphenols and phthalates, which is another im-
portant time period in early-life exposure to these chemicals and in
bone development. Further research is needed to explore the associa-
tions of neonatal exposure to bisphenols and phthalates with childhood
bone mass. Both bisphenols and phthalates are reported to have short
biological half-lives (< 24 h) (Mattison et al., 2014; Braun et al., 2013).
However, it has been suggested that a single urine sample for phthalate
concentrations reasonably reflects exposure for up to 3 months (Hauser
et al., 2004). Variability has been reported to be biomarker specific,
with reasonable correlations for BPA and DEHP metabolites and
stronger correlations for LMW phthalate metabolites and mono-
benzylphthalate (Braun et al., 2012; Mahalingaiah et al., 2008). In our
study, we observed high variability for bisphenols and moderate
variability for phthalates across pregnancy. A previous study has re-
ported that between two and four weekly pools of 20 urines would be
needed to properly classify women in terms of phthalate metabolites
and bisphenol levels (Casas et al., 2018). Thus, by relying on a single-
spot urinary measurement of phthalate metabolites and bisphenols as
an estimate of exposure per trimester, our analyses may be affected by
measurement error, which may have led to underestimation of the ef-
fect estimates, especially for bisphenols. Finally, we collected in-
formation on many potential confounding variables. However, as in any
observational study, residual confounding due to unmeasured lifestyle
variables might still be an issue.
5. Conclusion
Our study suggests that bone health in school-aged children may be
influenced by fetal endocrine disruptor exposure, specifically BPS, in
first trimester. However, due to the observational design of our study,
these findings should be carefully interpreted, considered as hypothesis
generating and need further replication and exploration of underlying
mechanisms.
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